So Antwort von RedHill ist gekommen..(sogar zum Sonntag)
u.a.
"We understand your frustration. Thank you for your patience, trust and support. It is important for us to be transparent with our shareholders and provide comprehensive feedback to your queries, as much as possible. You may or may not know this but shareholders will always find us highly responsive to your queries, in good and bad times alike. We appreciate you raising your concerns. As you probably know, RedHill has a lot going on with a broad late-stage pipeline and commercial infrastructure in the U.S. Although we are a relatively small company, we believe that it is in the best interest of patients suffering from this pandemic and in the interest of our shareholders, that we make an effort to develop two of RedHill’s promising late-stage assets (opaganib and RHB-107/upamostat) for COVID-19. RedHill’s two shots on goal for COVID-19 (opaganib for hospitalized patients and RHB-107 for non-hospitalized patients) are at the very forefront of the global race for effective new treatments. The team is working very hard and are fully committed to develop these assets for COVID-19, for those patients in urgent need of new treatments. These studies require additional funding and so the two recent financing rounds provided RedHill the opportunity to raise the funds to support the studies on top of the additional broad activities. We consider a strong balance sheet to be the balanced and responsible approach given the surrounding circumstances. RedHill’s management team is committed to execute the business to maximize its stakeholders’ benefit, including shareholders, patients and employees. Although we have no control over the share price, we do hope that RedHill’s stakeholders will be able to benefit from our activities in the longer-term. Attached please find our latest corporate presentation. We appreciate your patience and support and remain available should you have any additional questions. Best regards, Alexandra "
(RDHL) Mkap $61 M /Ein MUSS für jeden Biotech Investor | wallstreet-online.de - Vollständige Diskussion unter:
www.wallstreet-online.de/diskussion/...vestor#neuster_beitrag